The most recent trading session ended with Moderna (MRNA) standing at $34.71, reflecting a +0.26% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain of 0.64%.

A senior official at the NIH's National Cancer Institute confirmed to KFF that NIH acting Director Matthew Memoli "sent an ...

As we near the five-year anniversary of the COVID-19 pandemic, it's a good time to revisit the drugmaker stock that was top ...

Moderna (NASDAQ:MRNA) shares jumped 16% on Wednesday, March 5, following a favorable German court decision that determined ...

The Florida surgeon general in January 2024 called for a halt in the use of COVID mRNA vaccines. And in Texas, Attorney ...

Citigroup assumed coverage on shares of Moderna (NASDAQ:MRNA – Free Report) in a research report report published on Thursday ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

A few years ago, Moderna (NASDAQ: MRNA) stock soared on the back of the highly successful vaccine it developed in record time. At its peak in 2021, Moderna traded for over $450 per share.

In terms of liquidity and interest, the mean open interest for Moderna options trades today is 3103.07 with a total volume of 1,821.00. In the following chart, we are able to follow the development of ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

Moderna (MRNA) stock is climbing 8% after the drug maker won a key court case and its CEO bought shares on the open market.

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic insider stock purchases by the CEO and director. This comes as a significant ...